@article {SAITO5635, author = {TAKASHI SAITO and KAYOKO OHNISHI and HITOSHI ISHIKAWA and MASATOSHI NAKAMURA and SODAI HOSHIAI and HARUKO NUMAJIRI and KEIKO NEMOTO MUROFUSHI and MASASHI MIZUMOTO and TOSHIYUKI OKUMURA and HIDEYUKI SAKURAI}, title = {Hypofractionated Proton Beam Therapy for cT1-2N0M0 Non-small Cell Lung Cancer Patients With Interstitial Lung Disease}, volume = {41}, number = {11}, pages = {5635--5642}, year = {2021}, doi = {10.21873/anticanres.15379}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: To evaluate the outcomes of proton beam therapy (PBT) for early-stage non-small cell lung cancer (NSCLC) in patients with interstitial lung disease (ILD). Patients and Methods: Between 2002 and 2017, 110 patients receiving hypofractionated PBT for cT1-2N0M0 NSCLC were reviewed. Results: Of the 110 patients, 17 were diagnosed with ILD. The median follow-up period was 37.8 months. No significant difference in the 1-year cumulative rate of grade >=2 pneumonitis was observed between patients with and those without ILD (17.6\% vs. 14.1\%, p=0.708). The lung doses were significantly lower in patients with than in those without ILD among patients without grade >=2 pneumonitis. There were no significant differences in overall survival or local recurrence-free rates according to the presence of ILD. Conclusion: PBT appears to be a feasible and effective treatment for cT1-2N0M0 NSCLC in patients with ILD, but the lung dose should be strictly reduced.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/41/11/5635}, eprint = {https://ar.iiarjournals.org/content/41/11/5635.full.pdf}, journal = {Anticancer Research} }